...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Biomedical Research >Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients
【24h】

Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients

机译：他汀类药物治疗和肝毒性：高脂血症患者中阿托伐他汀的安全性评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Statins are one of the most frequently prescribed medications to reduce the risk of cardiovascular events. Statins appear to be safe however, there are contradictory data regarding their adverse effects, which might be due to genetic variation in their metabolism. Hence, this prospective study was aimed to evaluate the effects of atorvastatin on liver transaminase changes in a clinical setting, in north Iran. Materials and Methods: This prospective semi-experimental study was performed on hyperlipidemic adults in 2010-2011. Patients received atorvastatin (5-40 mg/d) based on the American National Cholesterol Education Program guidelines. Liver aminotransferases were measured in three occasions of baseline, 8 and 16 weeks period. Results: A total of 206 patients were included in the study. Of which 178 were female and 30 were male. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were in normal range before intervention in the majority, except in 25 (12.1%) and 16 (7.8%) of patients, respectively. In general, ALT and AST remained in normal range over the study period (23.3 IU/L and 21.8 IU/L, respectively). There was found no relationship between different doses of atorvastatin prescribed and ALT/AST changes in the patients. The males' ALT means at baseline (26.9 IU/L), 8 weeks (30 IU/L) and 16 weeks (28.8 IU/L) after statin therapy were significantly higher than females (22 IU/L, 22.2 IU/L and 22.1 IU/L, respectively; P Conclusion: The absence of any hepatic adverse effect in the present study supports safety of atorvastatin and emerging opinion that routine screening of liver function tests is not necessary in patients on statins.
机译：背景：他汀类药物是减少心血管事件风险的最常用处方药物之一。他汀类药物似乎是安全的，但是关于它们的不良作用却有相互矛盾的数据，这可能是由于其代谢的遗传变异所致。因此，这项前瞻性研究旨在评估伊朗北部临床环境中阿托伐他汀对肝脏转氨酶变化的影响。材料和方法：这项前瞻性半实验研究于2010-2011年在高脂血症成年人中进行。根据美国国家胆固醇教育计划指南，患者接受阿托伐他汀（5-40 mg / d）。在基线期，第8周和第16周的三种情况下测量了肝转氨酶。结果：总共206名患者被纳入研究。其中女性为178人，男性为30人。在大多数干预之前，丙氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）处于正常范围，但分别有25（12.1％）和16（7.8％）的患者除外。通常，在研究期间，ALT和AST保持在正常范围内（分别为23.3 IU / L和21.8 IU / L）。在患者中，处方不同剂量的阿托伐他汀与ALT / AST变化之间没有关系。他汀类药物治疗后男性的ALT平均值在基线（26.9 IU / L），8周（30 IU / L）和16周（28.8 IU / L）显着高于女性（22 IU / L，22.2 IU / L和分别为22.1 IU / L; P结论：本研究中没有任何肝不良反应支持阿托伐他汀的安全性，并且出现了新的观点，即对他汀类药物的患者无需常规肝功能检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号